Lebrikizumab for adolescent atopic dermatitis: 24-week
real-world outcomes from the Czech BIOREP registry

J 2026

Lebrikizumab for adolescent atopic dermatitis: 24-week real-world outcomes from the Czech BIOREP registry

ROB, Filip; Blanka PINKOVÁ; Petra GKALPAKIOTI; Jirina BARTONOVA; Jiri HORAZDOVSKY et al.

Základní údaje

Originální název

Lebrikizumab for adolescent atopic dermatitis: 24-week real-world outcomes from the Czech BIOREP registry

Autoři

ROB, Filip; Blanka PINKOVÁ; Petra GKALPAKIOTI; Jirina BARTONOVA; Jiri HORAZDOVSKY; Jan RICAR; Jana TRESNAK HERCOGOVA a Kristyna SOKOLOVA

Vydání

JAAD INTERNATIONAL, AMSTERDAM, ELSEVIER, 2026, 2666-3287

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30216 Dermatology and venereal diseases

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.200 v roce 2024

Označené pro přenos do RIV

Ano

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

adolescent; atopic dermatitis; effectiveness; lebrikizumab; safety

Štítky

14110317, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 4. 2026 09:18, Mgr. Tereza Miškechová

Anotace

V originále

Lebrikizumab, a novel anti-interleukin-13 antibody for atopic dermatitis (AD), has demonstrated efficacy and safety in clinical trials in adults and adolescents; however, real-world evidence in adolescents remains limited.1,2 This analysis evaluates the effectiveness and safety of lebrikizumab over 24 weeks in adolescents enrolled in the Czech BIOREP registry. The study included 32 adolescent patients with moderate-to-severe AD who received an initial lebrikizumab dose from September 2024 to August 2025 (Table I). Of these, 30 patients (93.8%) attended at least 1 follow-up visit at week 16, and 25 (78.1%) completed the second follow-up at week 24. Only patients with baseline itch numeric rating scale (NRS) scores ≥4 (30/32) were evaluated for achieving an improvement of ≥4-point improvement. Throughout the study, patients continued to use moisturizers and various topical therapies as needed.

Citovat

ROB, Filip; Blanka PINKOVÁ; Petra GKALPAKIOTI; Jirina BARTONOVA; Jiri HORAZDOVSKY; Jan RICAR; Jana TRESNAK HERCOGOVA a Kristyna SOKOLOVA. Lebrikizumab for adolescent atopic dermatitis: 24-week real-world outcomes from the Czech BIOREP registry. JAAD INTERNATIONAL. AMSTERDAM: ELSEVIER, 2026, roč. 25, April 2026, s. 130-132. ISSN 2666-3287. Dostupné z: https://doi.org/10.1016/j.jdin.2026.01.009.

@article{2564444,
   author = {Rob, Filip and Pinková, Blanka and Gkalpakioti, Petra and Bartonova, Jirina and Horazdovsky, Jiri and Ricar, Jan and Tresnak Hercogova, Jana and Sokolova, Kristyna},
   article_location = {AMSTERDAM},
   article_number = {April 2026},
   doi = {https://doi.org/10.1016/j.jdin.2026.01.009},
   keywords = {adolescent; atopic dermatitis; effectiveness; lebrikizumab; safety},
   language = {eng},
   issn = {2666-3287},
   journal = {JAAD INTERNATIONAL},
   title = {Lebrikizumab for adolescent atopic dermatitis: 24-week real-world outcomes from the Czech BIOREP registry},
   url = {https://www.sciencedirect.com/science/article/pii/S2666328726000131?via%3Dihub},
   volume = {25},
   year = {2026}
}

TY  - JOUR
ID  - 2564444
AU  - Rob, Filip - Pinková, Blanka - Gkalpakioti, Petra - Bartonova, Jirina - Horazdovsky, Jiri - Ricar, Jan - Tresnak Hercogova, Jana - Sokolova, Kristyna
PY  - 2026
TI  - Lebrikizumab for adolescent atopic dermatitis: 24-week real-world outcomes from the Czech BIOREP registry
JF  - JAAD INTERNATIONAL
VL  - 25
IS  - April 2026
SP  - 130-132
EP  - 130-132
PB  - ELSEVIER
SN  - 26663287
KW  - adolescent
KW  - atopic dermatitis
KW  - effectiveness
KW  - lebrikizumab
KW  - safety
UR  - https://www.sciencedirect.com/science/article/pii/S2666328726000131?via%3Dihub
N2  - Lebrikizumab, a novel anti-interleukin-13 antibody for atopic dermatitis (AD), has demonstrated efficacy and safety in clinical trials in adults and adolescents; however, real-world evidence in adolescents remains limited.1,2 This analysis evaluates the effectiveness and safety of lebrikizumab over 24 weeks in adolescents enrolled in the Czech BIOREP registry. The study included 32 adolescent patients with moderate-to-severe AD who received an initial lebrikizumab dose from September 2024 to August 2025 (Table I). Of these, 30 patients (93.8%) attended at least 1 follow-up visit at week 16, and 25 (78.1%) completed the second follow-up at week 24. Only patients with baseline itch numeric rating scale (NRS) scores ≥4 (30/32) were evaluated for achieving an improvement of ≥4-point improvement. Throughout the study, patients continued to use moisturizers and various topical therapies as needed.
ER  -

ROB, Filip; Blanka PINKOVÁ; Petra GKALPAKIOTI; Jirina BARTONOVA; Jiri HORAZDOVSKY; Jan RICAR; Jana TRESNAK HERCOGOVA a Kristyna SOKOLOVA. Lebrikizumab for adolescent atopic dermatitis: 24-week real-world outcomes from the Czech BIOREP registry. \textit{JAAD INTERNATIONAL}. AMSTERDAM: ELSEVIER, 2026, roč.~25, April 2026, s.~130-132. ISSN~2666-3287. Dostupné z: https://doi.org/10.1016/j.jdin.2026.01.009.

Přehled o publikaci